Horizon Pharma gets U.K. marketing authorization for DUEXIS Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted marketing authorization for DUEXIS for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Horizon Pharma price target raised to $18 from $16 at JMP Securities JMP Securities increased its price target on Horizon as the firm reports that the company's Vimovo drug is outpacing the firm's early expectations. The firm thinks the company could increase its 2014 guidance on its upcoming Q4 earnings call. JMP Securities expects the stock to rise following the earnings, and recommends owning the shares ahead of the results. It reiterates an Outperform rating on the shares.